Page 180 - Haematologica Vol. 109 - July 2024

ARTICLE - ASCT in refractory or early relapsed DLBCL
prepared the first draft of the manuscript. AMT and SM collected and assembled data. All authors analyzed and interpreted data, reviewed and revised the manuscript, and approved the final version.
References
1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
2. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790-795.
3. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
4. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045.
5. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
6. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127.
7. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184.
8. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022.
9. Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066-1073.
10. Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1729-1736.
11. Tun AM, Maliske S, Wang Y, et al. Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma. Transplant Cell Ther. 2022;28(9):610-617.
12. Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood. 2021;137(10):1416-1423.
13. Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure
A.M. Tun et al. This article includes the data supporting the findings and
interpretation of the results. Please contact the correspond- ing authors for additional data.
of front-line immunochemotherapy. Br J Haematol.
2017;179(1):50-60.
14. Wang Y, Farooq U, Link BK, et al. Late relapses in patients with
diffuse large B-cell lymphoma treated with
immunochemotherapy. J Clin Oncol. 2019;37(21):1819. 15. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene
ciloleucel as second-line therapy for large B-cell lymphoma. N
Engl J Med. 2022;386(7):640-654.
16. Bishop MR, Dickinson M, Purtill D, et al. Second-line
tisagenlecleucel or standard care in aggressive B-cell
lymphoma. N Engl J Med. 2022;386(7):629-639.
17. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene
maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second- line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysi. Lancet. 2022;399(10343):2294-2308.
18. Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract. 2022;18(12):800-807.
19. Perales M-A, Anderson LD, Jain T, et al. Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2022;28(9):546-559.
20. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-1545.
21. Wudhikarn K, Johnson aM, Inwards DJ, et al. Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic cohort analysis. Transplant Cell Ther. 2023;29(3):176.e1-176.e8.
22. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191-192.
23. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
24. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
25. Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy. Transplant Cell Ther. 2021;27(1):55.e1-55.e7.
26. Cherng HJ, Xu G, Feng L, et al. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023;200(1):35-44.
27. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
28. Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant
Data-sharing statement
Haematologica | 109 July 2024
2194